Serina Therapeutics receives FDA clearance for SER-252 IND in advanced Parkinson's

Serina Therapeutics, Inc.

FDA cleared IND for SER-252, an investigational therapy for advanced Parkinson's disease.
Phase 1b registrational study to start; site and regulatory activities in Australia underway.
FDA alignment on 505(b)(2) NDA pathway provides clear development path for SER-252.
CEO Steve Ledger calls milestone a major step toward addressing significant unmet need.

item 8.01item 9.01

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.